Obesity - a protective factor in dialysis patients?

Česká verzia

Authors: D. Ližičárová; E. Hirnerová; B. Krahulec; Ľ. Gašpar; M. Kučera; Z. Bartošová
Authors place of work: II. Interná klinika Lekárskej fakulty Univerzity Komenského a Univerzitnej nemocnice Bratislava, Prednosta: doc. MUDr. Ľudovít Gašpar, CSc.
Published in the journal: Prakt. Lék. 2012; 92(5): 264-266
Category: Of different specialties

Summary

Obesity in the general population is considered to be a risk factor for the development of cardiovascular diseases and malignant tumour diseases as well as a risk factor for other vascular risk factors (angiometabolic X syndrome, type 2 diabetes, dyslipidaemia, hypertension, hyperuricemia etc.) Last but not least, obesity is also a risk factor for other diseases such as sleep apnoea syndrome, osteoarthritis, gout and non-alcoholic fatty liver disease. However, according to existing studies, among the group of dialysis patients obesity appears to be paradoxically a protective factor in the development of cardiovascular diseases. This phenomenon in dialysis patients is referred to as a “risk factor paradox”. Nevertheless, studies which disprove the protective effect of obesity in dialysis patients exist. This article provides an overview of the obesity’s position in dialysis patients in existing studies.

Key words:
obesity, chronic kidney disease, dialysis patients, „risk factor paradox“

Zdroje

1. Abbott, K.C., Glanton, C.W., Trespalacios, F.C. et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int. 2004, 65, p. 597–605.

2. Agarwal, R. Body mass index-mortality paradox in hemodialysis: can it be explained by blood pressure? Hypertension 2011, 58, p. 1014–1020.

3. Degoulet, P., Legrain, M., Reach, I. et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982, 31, p. 103–110.

4. Dukát, A., Lietava, J., Krahulec, B. a kol. IDEA–Prvé výsledky o prevalencii abdominálnej obezity na Slovensku. Via. pract. 2006, 3, s. 554–558.

5. Ejerblad, E., Fored, C.M., Lindblad, P. et al. Obesity and risk for chronic renal failure. J. Am. Soc. Nephrol. 2006, 17, p. 1695–1702.

6. Elsayed, E.F., Sarnak, M.J., Tighiouart, H. et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am. J. Kidney Dis. 2008, 52, p. 29–38.

7. Fleischmann, E.H., Bower, J.D., Salahudeen, A.K. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J. 2001, 47, p. 74–81.

8. Foley, R.N., Parfrey, P.S., Sarnak, M.J. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998, 9, p. 16–23.

9. Foster, M.C., Hwang, S.J., Larson, M.G. et al. Overweight, obesity and the development of stage 3 CKD: the Framingham Heart Study. Am. J. Kidney Dis. 2008, 52, p. 39–48.

10. Fox, C.S., Larson, M.G., Leip, E.P. et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004, 291, p. 844–850.

11. Gavorník, P. Arteriológia a mikrocirkulatológia. In Gavorník, P. Všeobecná angiológia, 2. vyd., Bratislava: Univerzita Komenského, 2001: 268 (s. 81-187). ISBN 80-223-1608-3.

12. Gavorník P. Končatinovocievne ischemické choroby. B 2.1: 1-92. In: Gavorník P, Hrubiško M, Rozborilová E (eds). Diferenciálna diagnostika kardio-vaskulárnych, respiračných a hematologických ochorení. I. 1. vyd. Bratislava: Dr. Josef Raabe, 2010: 300. ISBN 978-80-89182-46-6.

13. Gavorník P. Manažment stabilnej angíny pektoris. Medikom 2011; 1(4): 12–14.

14. Gavorník P. Obliterujúce choroby artérií a končatinovocievna ischemická choroba. Nová klinicko-etiologicko-anatomicko-patofyziologická (CEAP) klasifikácia. Cardiology 2010; 19 (3): 201–213.

15. Gelber, R.P., Kurth, T., Kausz, A.T. et al. Association between body mass index and CKD in apparently healthy men. Am. J. Kidney Dis. 2005, 46, p. 871–880.

16. Goumenos, D.S., Kawar, B., Nahas, M. et al. Early histological changes in the kidney of people with morbid obesity. Nephrol. Dial. Transplant. 2009, 24, p. 3732–3738.

17. Hsu, C.Y., McCulloch, C.E., Irabarren, C. et al. Body mass index and risk for end-stage renal disease. Ann. Intern. Med. 2006, 144, p. 21–28.

18. Chazot, C., Gassia, J.P., Di Benedetto, A. et al. Is there any survival advantage of obesity in Southern European haemodialysis patients? Nephrol. Dial. Transplant. 2009, 25, p. 2871–2876.

19. Iseki, K., Ikemiya, Y., Kinjo, K. et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004, 65, p. 1870–1876.

20. Johansen, K.L., Young, B., Kaysen, G.A., Chertow, G.M. Association of body size with outcomes among patients beginning dialysis. Am. J. Clin. Nutr. 2004, 80, p. 324-332.

21. Kalantar-Zadeh, K., Block, G., Humphreys, M.H., Kopple, J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003, 63, p. 793–808.

22. Kalantar-Zadeh, K., Kopple, J.D., Kilpatrick, R.D. et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am. J. Kidney Dis. 2005, 46, p. 489–500.

23. Kalantar-Zadeh, K., Kopple, J.D. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am. J. Kidney Dis. 2001, 38, p. 1343–1350.

24. Kalantar-Zadeh, K., Streja, E., Kovesdy, C.P. et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin. Proc. 2010, 85, p. 991–1001.

25. Kumakura, H., Kanai, H., Aizaki, M. et al. The influence of the obesity paradox and chronic kidney disease on long-term survival in a Japanese cohort with peripheral arterial disease. J. Vasc. Surg. 2010, 52, p. 110–117.

26. Lavie, C.J., Milani, R., Ventura, H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 2009, 53, p. 1925–1932.

27. Lean, M.E. Obesity: burdens of illness and strategies for prevention or management. Drugs Today 2000, 36, p. 773–784.

28. Leavey, S.F., McCullough, K., Hecking, E. et al. Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol. Dial. Transplant. 2001, 16, p. 2386–2394.

29. Marti, S., Munoz, X., Rios, J. et al. Body weight and comorbidity predict in COPD patients treated with oxygen therapy. Eur. Respir. J. 2006, 27, p. 689–696.

30. Munkhaugen, J., Lydersen, S., Wideroe, T.E., Hallan, S. Prehypertension, obesity and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am. J. Kidney Dis. 2009, 54, p. 638–646.

31. Navarro, W.H., Loberiza, F.R., Bajorunaite, R. et al. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2006, 12, p. 541–551.

32. Odgen, C.L., Yanovski, S.Z., Carroll, M.D., Flegal, K.M. The epidemiology of obesity. Gastroenterology 2007, 132, p. 2087–2102.

33. Pinto-Sietsma, S.J., Navis, G., Janssen, W.M. et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am. J. Kidney Dis. 2003, 41, p. 733–741.

34. Port, F.K., Ashby, V.B., Dhingra, R.K. et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J. Am. Soc. Nephrol. 2002, 13, p. 1061–1066.

35. Rufino, J.M., García, C., Vega, N. et al. Current peritoneal dialysis compared with haemodialysis: medium-term survival analysis of incident dialysis patients in the Canary Islands in recent years. Nefrologia 2011, 31, p. 174–184.

36. Ryu, S., Chang, Y., Woo, H.Y. et al. Changes in body weight predict CKD in healthy men. J. Am. Soc. Nephrol. 2008, 19, p. 1798–1805.

37. Sanabria, M., Muñoz, J., Trillos, C. et al. Dialysis outcomes in Colombia (DOC) study: a comparison of patient survival on peritoneal dialysis vs hemodialysis in Colombia. Kidney Int. Suppl. 2008, 108, p. 165–172.

38. Souček, M. Metabolický syndrom. Vnitř. Lék. 2009, 55, s. 618–621.

39. Svačina, Š. Léčba obezity u metabolického syndrómu. Vnitř. Lék. 2009, 55, s. 622–625.

40. Valocikova, I., Valocik, G., Kristofova, B., Druzbacka, L. Obesity paradox and chronic kidney disease. Bratisl. Lek. Listy 2011, 112, s. 402–406.

41. Wang, Y., Beydoun, M.A. The obesity epidemic in the United States—gender, age, socioeconomic, racial/ethnic, and geographic characteristics. a systematic review and meta-regression analysis. Epidemiol. Rev. 2007, 29, p. 6–28.

42. Wang, Y., Chen, X., Song, Y., Cheskin, L.J. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008, 73, p. 19–33.

43. Zamora, E., Lupón, J., Antonio, M. et al. The obesity paradox in heart failure: Is etiology a key factor? Int. J. Cardiol. 2011, Epub ahead of print.

44. Zhang, C., Rexrode, K.M., Dam, R.M. et al. Abdominal obesity and the risk of all-cause, cardiovascular and cancer mortality: sixteen years of follow-up in US women. Circulation 2008, 117, p 1658–1667.